CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elstar Therapeutics, a company fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating multi-functional therapies, today announced that Steve Arkinstall, President and CEO of Elstar Therapeutics, will present at the Bloomberg Biotech Innovations Conference taking place on April 9, 2018 in New York, NY.
Elstar is rapidly building an early pipeline of differentiated immunotherapies able to engage selected cells of the adaptive and innate immune system and at the same time exhibit precision targeting to the tumor microenvironment to avoid toxicity on healthy cells. Underpinning this, Elstar also continues to expand the capabilities of its UniTI™ platform including a novel approach for generating bispecific therapeutic human antibodies.
Details of the presentations are as follows:
Bloomberg Biotech Innovations Conference
Title: UniTI: Efficacy, Precision & COGS
Date: Monday, April 9, 2018
Time: 3:30 PM ET
Location: 731 Lexington Avenue, New York, NY
About Elstar Therapeutics, Inc.
Elstar Therapeutics is fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating antibody-based, multi-functional therapeutics.
Armed with a unique approach to engaging multiple immune mechanisms, Elstar enables patients to harness their own body to fight cancer.
Elstar’s Universal Targeted Immunotherapy (UniTI™) platform is positioned to overcome barriers that are limiting the full potential of other promising immunotherapeutic approaches.
“Our motivation…to be part of the cure for cancer.”
For more information visit www.elstartherapeutics.com